Dana Goldman, PhD
Co-Director, USC Schaeffer Center for Health Policy & Economics
Dean, USC Price School of Public Policy
Distinguished Professor of Pharmacy, Public Policy and Economics
Dean Goldman is also a nationally-recognized scholar. He is the author of more than 300 articles in medicine, health policy, economics, and statistics; and his work has been cited more than 19,000 times according to Google Scholar. He pioneered a “Netflix model” to improve access to prescription drugs and the value of reduced copayments for the chronically ill. He has served as a health policy advisor to the Congressional Budget Office, Covered California, Fred Hutchinson Cancer Institute, and National Institutes of Health. He served on the boards of ISPOR and ASHEcon and the editorial boards of Health Affairs and other journals. His research and opinion pieces have appeared in the New York Times, Wall Street Journal, Washington Post, Stat, Forbes, Business Week, U.S. News & World Report, The Economist, NBC Nightly News, PBS NewsHour, CNN, NPR, and other media.
Dean Goldman is an elected member of the National Academy of Medicine and the National Academy of Social Insurance. In 2016, he was appointed a Distinguished Professor at USC in recognition of bringing the university “special renown.” He is a past recipient of the USC Mellon Mentoring Award and several other teaching and research awards.
Dean Goldman has been strongly committed to mentoring students and junior faculty throughout his career. He was a founding director of USC’s Resource Center for Minority Aging Research funded by NIH. The program aims to help increase the diversity and academic success of junior faculty. Past trainees from this and other mentorship include faculty at Stanford, Harvard, Duke, UCLA, UCSF, World Bank, University of Pennsylvania, and Vanderbilt. He was a co-founder of Precision Health Economics—a consultancy that provided analytic services to pharmaceutical, biological and health care companies. He currently serves as a scientific advisor to GRAIL and Biogen. He also spent 15 years at the RAND Corporation, where he held the Distinguished Chair in Health Economics and served as director of its health economics program and the Bing Center.
Dean Goldman received his B.A. summa cum laude from Cornell University and his Ph.D. in Economics from Stanford University.
Health Policy & Management
Economics (Summa cum Laude), Cornell University- 1988
Economics, Stanford University- 1994
- Member, National Academy of Social Insurance- 2018
- Inaugural Associate Member, Center for the Economics of Human Development- 2018
- Associates Award for Creativity in Research, University of Southern California- 2017
- Distinguished Professor, University of Southern California- 2016
- Robert Biller Outstanding Faculty Award, Price School of Public Policy- 2015
- USC Mellon Mentoring Award- 2012
- MetLife Foundation Silver Scholar Award- 2011
- Member, National Academy of Medicine- 2009
- Eugene Garfield Economic Impact of Medical and Health Research Award-2009
- Edwin E. Huddleson, Jr. Outstanding Teacher Award, RAND Graduate School-2006
- Annual Research Award, National Institute for Health Care Management-2002
- Alice S. Hersh New Investigator Award, AcademyHealth- 2002
- Article of the Year, Association for Health Services Research-2000
- Stanford University Fellowship in Health Care Research and Health Policy-1993
- John M. Olin Fellowship for Research in Economic Policy-1992
- Summa Cum Laude with Distinction in All Subjects, Cornell University-1988
- Phi Beta Kappa, Cornell University-1988
- National Merit Scholar-1984
- Leonard D. Schaeffer Director’s Chair and Distinguished Professor of Public Policy, Pharmacy, and Economics (Gerontology by courtesy)
- University of Southern California, 2013-Present
- ACADIA Pharmaceuticals Scientific Advisory Board, 2017-Present
- Nonresident Senior Fellow, Economic Studies Program, Brookings Institution, 2017-Present
- Fred Hutchinson Cancer Institute, HICOR Advisory Board (Chair), 2013-Present
- Director, NIA Roybal Center for Health Policy Simulation, 2004-Present
- Research Associate, National Bureau of Economic Research, 2002-Present
Trish et al. “Who Pays in Medicare Part D? Giving Plans More Skin in the Game.” NEJM, forthcoming.
Goldman D, et al. “A New Model for Pricing Drugs of Uncertain Efficacy.” NEJM Catalyst, Published online December 13, 2018.
Dzau V, Ginsburg G, Van Nuys K, Goldman D. “Aligning incentives to fulfil the promise of personalized medicine.” The Lancet, 385(9982):2015-2120, May 6, 2015.
Goldman D, Philipson T. “Five myths about cancer care in America.” Health Affairs, 33(10):1801-4, 2014.
Goldman D, Cutler D, Rowe J, et al. “Substantial Health and Economic Returns From Delayed Aging May Warrant a New Focus For Medical Research.” Health Affairs, 32(10):1698-1705, 2013.
Lakdawalla D, Sun E, Jena A, Reyes C, Goldman D, Philipson T. “An Economic Evaluation of the War on Cancer.” Journal of Health Economics, 29(1):333-346, May 2010.
Goldman D, Joyce G, Zheng Y. “Prescription Drug Cost Sharing: Association With Medication and Medical Utilization and Spending and Health.” JAMA, 298(1):61-69, 2007.
Goldman D, Joyce G, Escarce J, Pace J, Solomon M, Laouri M, Landsman P, Teutsch S. “Pharmacy Benefits and The Use Of Drugs By The Chronically-Ill.” JAMA, 291(19):2344-50, 2004.
Goldman D, Berry S, McCabe M, et al. “The Incremental Costs of NCI-Sponsored Clinical Trials.” JAMA, 289(22):2970-2977, 2003.
Goldman D, Smith J. “Can Patient Self-Management Help Explain the SES Health Gradient?” Proceedings of the National Academy of Sciences, 99(16):10929-10934, 2002.